Tag archive for ‘Medac’
Antares; My View of How Otrexup and Medac’s New Product Rasuvo May Compete (ATRS, Buy, $2.54)
Investors Are Concerned About Rasuvo’s Impact on Otrexup Investors have been concerned about the potential effect on Otrexup if the private company Medac gains approval for Rasuvo. Both products are device drug combinations that use highly engineered and proprietary auto injectors to administer methotrexate as a sub-cutaneous injection. These products were both developed under the […]
Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)
Recent Price Behavior Antares’ (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and psoriasis on October 14, 2013. Antares launched Otrexup on January 15, 2014 for the treatment of rheumatoid arthritis and on March 3, 2014, its partner LEO launched Otrexup for psoriasis. Last October, the price […]